1. Hall SF, Irish J, Groome P, Griffiths R. Access, excess, and overdiagnosis: the case for thyroid cancer. Cancer Med. 2014;3:154–61. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3930400&tool=pmcentrez&rendertype=abstract
.
2. Brito JP, Morris JC, Montori VM. Thyroid cancer : zealous imaging has increased detection and treatment of low risk tumours. Bmj. 2013;4706:1–6. Available from:
http://dx.doi.org/doi:10.1136/bmj.f4706
.
3. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011. Bethesda: National Cancer Institute.
http://seer.cancer.gov/csr/1975_2011/
, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
4. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56:531–8.
5. Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulos KP, et al. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer. 2014;120:1345–52.